Last reviewed · How we verify
Sevorane (sevoflurane, Abbott)
Sevorane (sevoflurane, Abbott) is a Volatile anesthetic Small molecule drug developed by Medical University of Gdansk. It is currently FDA-approved for Induction and maintenance of general anesthesia in adults and pediatric patients, Sedation in intensive care settings. Also known as: sevoflurane.
Sevoflurane is a volatile anesthetic that depresses the central nervous system by enhancing inhibitory GABA neurotransmission and inhibiting excitatory glutamate signaling.
Sevoflurane is a small molecule that acts as a positive modulator of the glycine receptor (alpha-1/beta). It is used for inhalative sedation in ICU settings, with studies comparing its effects to propofol.
At a glance
| Generic name | Sevorane (sevoflurane, Abbott) |
|---|---|
| Also known as | sevoflurane |
| Sponsor | Medical University of Gdansk |
| Drug class | Volatile anesthetic |
| Target | GABA-A receptor, NMDA glutamate receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | FDA-approved |
Mechanism of action
Sevoflurane is a halogenated ether that acts as a general anesthetic by modulating ion channels and neurotransmitter receptors in the brain, particularly potentiating GABA-A receptors and blocking NMDA glutamate receptors. This results in rapid loss of consciousness, amnesia, and analgesia. It is administered via inhalation and is rapidly absorbed and eliminated through the lungs, making it suitable for induction and maintenance of general anesthesia.
Approved indications
- Induction and maintenance of general anesthesia in adults and pediatric patients
- Sedation in intensive care settings
Common side effects
- Postoperative nausea and vomiting
- Emergence delirium
- Hypotension
- Respiratory depression
- Hepatotoxicity (rare)
Key clinical trials
- COGNITIVE - Cognitive Function After Sevoflurane or Propofol Anesthesia for Open-heart Operations (PHASE4)
- Endotracheal Intubation With Sevoflurane in Surgical Pediatric Patients (NA)
- Sevoflurane Sedation on Intra Cranial Pressure in Traumatic Brain Injury Patients (PHASE2)
- Two Different Preparations of Sevoflurane in Induction (PHASE4)
- Inhalative Sedation in ICU With Sevoflurane Via Anaesthetic Conserving Device Compared to Propofol
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sevorane (sevoflurane, Abbott) CI brief — competitive landscape report
- Sevorane (sevoflurane, Abbott) updates RSS · CI watch RSS
- Medical University of Gdansk portfolio CI
Frequently asked questions about Sevorane (sevoflurane, Abbott)
What is Sevorane (sevoflurane, Abbott)?
How does Sevorane (sevoflurane, Abbott) work?
What is Sevorane (sevoflurane, Abbott) used for?
Who makes Sevorane (sevoflurane, Abbott)?
Is Sevorane (sevoflurane, Abbott) also known as anything else?
What drug class is Sevorane (sevoflurane, Abbott) in?
What development phase is Sevorane (sevoflurane, Abbott) in?
What are the side effects of Sevorane (sevoflurane, Abbott)?
What does Sevorane (sevoflurane, Abbott) target?
Related
- Drug class: All Volatile anesthetic drugs
- Target: All drugs targeting GABA-A receptor, NMDA glutamate receptor
- Manufacturer: Medical University of Gdansk — full pipeline
- Therapeutic area: All drugs in Anesthesiology
- Indication: Drugs for Induction and maintenance of general anesthesia in adults and pediatric patients
- Indication: Drugs for Sedation in intensive care settings
- Also known as: sevoflurane
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing